Skip to main content

zolacabtagene autoleucel

Generic: Zolacabtagene Autoleucel

zolacabtagene autoleucel: 5 clinical trials tracked.

zolacabtagene autoleucel evidence translation

What we can confirm

5 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about zolacabtagene autoleucel, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (5)

A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

NCT07573332Registry updated 2026-07-17·Phase 1
Not yet recruiting

Primary endpoint: To evaluate the safety and tolerability of CC-97540 (BMS-986353) in participants with anti-AQP4 antibody positive NMO as determined by the proportion of patients experiencing DLTs

Interventionalopen5 targetStarted 2026-09Completion 2031-081 site · United StatesUniversity of Texas Southwestern Medical Center

A Phase I/II Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

NCT07388277Registry updated 2026-09-10·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Safety of CC-97540 in ANCA-Associated Vasculitis

Interventionalopen12 targetStarted 2026-03Completion 2029-121 site · United StatesMarcela V. Maus, M.D.,Ph.D.

A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)

NCT07015983Registry updated 2026-08-03·Phase 2
Active, not recruiting

Primary endpoint: Proportion of participants achieving drug-free Definition of Remission in Systemic Lupus Erythematosus (DORIS) remission

Interventionalopen89 targetStarted 2025-07Completion 2032-0650 sites · Argentina, Austria, Belgium, Brazil…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).

NCT06220201Registry updated 2026-08-03·Phase 1
Active, not recruiting

Primary endpoint: Number of participants with adverse events (AEs)

Interventionalopen120 targetStarted 2024-03Completion 2027-0734 sites · Belgium, France, Germany, Spain…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)

NCT05869955Registry updated 2026-08-03·Phase 1
Active, not recruiting

Primary endpoint: Number of participants with treatment-emergent adverse events (AEs) in each indication.

Interventionalopen270 targetStarted 2023-09Completion 2028-0846 sites · Belgium, France, Germany, Italy…Juno Therapeutics, Inc., a Bristol-Myers Squibb Company